Acute Ischemic StrokeESCAPE-MeVONCT05151172
EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)
A study testing endovascular thrombectomy (EVT) and Standarad medical care in people with Acute Ischemic Stroke, run by Dr. Michael D Hill at 53 sites in 4 countries.
Trial summary
Stroke occurs when a blood clot causes a blockage in a blood vessel (artery) within the brain. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. Stroke must be treated very fast. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Ischemic Stroke
- What is being tested?
- endovascular thrombectomy (EVT) and Standarad medical care
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 530 participants
- Where
- 53 sitesin 4 countries
- Study dates
- 15 Apr 2022to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Acute ischemic stroke clinically eligible for immediate EVT
- Age ≥18 years at the date of randomization
- Time from onset (or last-seen-well) to randomization <12 hours
- Disabling stroke defined as follows:
- baseline National Institutes of Health Stroke Scale (NIHSS) score >5 at the time of randomization
- NIHSS 3-5 with disabling deficit (eg. hemianopia, aphasia, loss of hand function) as determined by the attending physician in context of the patient's life situation
Show all 9Show fewer
- Confirmed symptomatic and endovascularly treatable MeVO based on neurovascular non-invasive imaging (mCTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P2 or P3 segment1.
- . Clinical deficit commensurate with MeVO occlusion location
- . Signed informed consent, two-physician consent, or deferral of consent where approved
Who cannot join
- ASPECTS ≤ 5
- The following depend on the imaging modality of the participating site:
- 9a. NCCT + mCTA
- Well demarcated hypodensity in the majority of the brain parenchyma supplied by the occluded vessel or absence of collaterals in the affected territory on the delayed phases of the mCTA OR 9b. NCCT + (m)CTA + CTP**
- Lack of core: penumbra mismatch (if the CTP is uninterpretable, e.g., due to motion artifacts, apply exclusion criteria from 9a. If single-phase CTA is performed, score collaterals accordingly. If NCCT + mCTA + CTP are all performed, the core: penumbra mismatch criteria are sufficient for exclusion) OR 9c. MRI
- Diffusion restriction in the majority of the brain parenchyma supplied by the occluded vessel
Show all 9Show fewer
- if MR perfusion is performed: lack of core:penumbra mismatch 10) Any evidence of intracranial hemorrhage on qualifying imaging 11) Patients living in a nursing home or requiring daily nursing care or assistance with activities of daily living.
- 12) Patient has a major co-morbid illness, such as severe dementia, advanced cancer, advanced heart failure etc. such that they are unlikely to be able to complete follow-up or they are unlikely to achieve the primary outcome due to the underlying illness (rather than the stroke or its treatment).
- 13) Pregnancy: female with positive urine or serum beta human chorionic gonadotropin (β-hCG) test 14) Participation in another clinical therapeutic intervention trial
Trial locations and contacts
53 sites in 4 countries.
53 sites in 4 countries
United States20 sites
University of Maryland
Baltimore, Maryland, 21201
bBston Medican Center
Boston, Massachusetts, 02118
Northwestern Medicine
Chicago, Illinois, 60611
Rush university Medical Centre
Chicago, Illinois, 60612
The Ohio State University
Columbus, Ohio, 43210
Ohio Health (Columbus ORI)
Columbus, Ohio, 43214
Baptist Health Medical Centre
Jacksonville, Florida, 32207
Mayo Clinic
Jacksonville, Florida, 32224
University of Kansas Medical Center
Kansas City, Kansas, 66160
Baptist Health Medical Center
Little Rock, Arkansas, 72205-7299
University of TN Health Sciences Centre
Memphis, Tennessee, 38163
Yale School of Medicine
New Haven, Connecticut, 06510
Mount Sinai Health System
New York, New York, 10029
Thomas Jefferson University
Philadelphia, Pennsylvania, 19017
Texas stroke Institute
Plano, Texas, 75075
Sutter Health
San Francisco, California, 94109
Swedish Medical Centre
Seattle, Washington, 98122
Tampa General Hospital
Tampa, Florida, 33606
University of Toledo
Toledo, Ohio, 43606
Providence Little company of Mary
Torrance, California, 90503
Canada14 sites
University of Calgary - Foothills Medical Centre
Calgary, Alberta, T2N2T9
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Health Sciences North
Greater Sudbury, Ontario, P3E 5J1
Queen Elizabeth II HSC
Halifax, Nova Scotia, B3H 3A7
Hamilton Health sciences
Hamilton, Ontario, L8L2X2
London Health Sciences
London, Ontario, N6A 5A5
Montreal Neurological Institute
Montreal, Quebec, H3A 2B4
Ottawa Hospital Research Institute
Ottawa, Ontario
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
St Michael's hospital
Toronto, Ontario, M5C 1R6
Toronto Western Hospital
Toronto, Ontario, M5T 2S8
Vancouver general hospital
Vancouver, British Columbia, V5Z 1M9
University of Manitoba
Winnipeg, Manitoba, RE3 3P5
United Kingdom13 sites
Royal Victoria Hospital
Belfast, BT12 6BA
Cambridge University Hospital
Cambridge, CB2 0QQ
Hull University Teaching Hospital
Hull, HU3 2JZ
Leeds Teaching Hospitals
Leeds, LS1 3EX
The Royal London Hospital
London, E1 !FR
Kings college Hospital
London, SE5 9RS
St Georges Hospital
London, SW17 0QT
Charing Cross Hospital
London, W6 8RF
University College London Hospital
London
Nottingham University Hospital
Nottingham, NG7 2UH
John Radcliffe Hopital
Oxford, OX3 9DU
University Hospital Southhampton
Southampton, SO16 6YD
Royal Stoke University Hospital
Stoke-on-Trent, Staffordshire, ST4 6QG
Germany6 sites
Klinikum Altenburger Lang
Altenburg, 04600
Albert-Ludwigs-Universität Freiburg
Freiberg, 79106
University of Heidelberg
Heidelberg
University Hospital Tübingen
Tübingen, 72076
University Hospital of Bonn
Venusberg, 53127
Wurzberg University Hospital
Würzburg, 97090
About this study
Official title: A Multicentre, Prospective, Randomized, Parallel Group, Open-label Design to Determine the Efficacy and Safety of Endovascular Thrombectomy for Ischemic Stroke Patients With Symptomatic Acute Medium Vessel Intracranial Occlusions
Stroke occurs when a blood clot causes a blockage in a blood vessel (artery) within the brain. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. Stroke must be treated very fast. Any delay of even 10 minutes can result in the difference between an independent and a disabled outcome, and in some cases between life and death. Endovascular therapy (EVT) or Thrombectomy is a procedure to remove the blood clot (thrombus) from a blood vessel to reopen it (recanalization). Patients are likely to benefit from a thrombectomy procedure when it is performed in a larger blood vessel. Currently it is not known if thrombectomy procedure will benefit the patients presenting with the stroke that has been caused by a blood clot in a medium sized blood vessel (medium vessel occlusion, MeVO). This trial will enrol patients diagnosed with acute stroke due to a clot in the medium sized vessel. The patients will be randomized within 12 hours of their symptom onset to either standard of care or standard of care plus thrombectomy procedure. The participation will last for 12 months Escape MeVO coordinating centre is located at the University of Calgary. There will be up to 75 sites. We will be recruiting a total of 530 patients.
Read the detailed description
ESCAPE-MeVO is a multicenter, prospective, randomized, open- label study with blinded endpoint evaluation (PROBE design). Participants will be randomized to routine best medical stroke care governed by current guidelines (control group) or to EVT plus best medical care. EVT will be performed with one of the Solitaire group of intracranial stent-retriever devices (Solitaire X, Medtronic) as the first line approach according to the manufacturers' specifications for use.
Patients with clinical symptoms of acute stroke, last seen normal within the last 12 hours, and with either NIHSS ≥ 5 or NIHSS 3-5 due to disabling symptoms in the judgement of the stroke team shall undergo imaging to identify the MeVO and assess the status of the affected brain parenchyma. As is being currently practiced across different stroke centers, imaging may follow different imaging paradigms:
- Option 1: NCCT + mCTA (first phase covers intracranial and extracranial vessels)
- Option 2: NCCT + mCTA/spCTA + either mCTA tissue level perfusion maps or CTP perfusion maps
- Option 3: DWI-MRI + MRA (of both the intracranial and extracranial vessels). Approach to the EVT procedure and technique will be at the discretion of the interventionist and team, with the exception that the first thrombectomy attempt is performed with one of the Solitaire group of intracranial stent-retriever devices (Solitaire X, Medtronic). Available, approved off-the-shelf, secondary devices may be used if reperfusion success is not achieved after use of the first device, at the discretion of the neuro-interventionalist
This study consists of one 90-day study period for each participant. Participants will be hospitalized for care after their acute stroke according to the current standard of care. Participants are required to return to clinic on Day 90 for end-of-study assessment.
- Conditions
- Acute Ischemic Stroke
- Being tested
- endovascular thrombectomy (EVT), Standarad medical care
- Keywords
- endovascular thrombectomy
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endovascular thrombectomy (EVT)Device
Also called solitaire X
minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
Standarad medical careOther
Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
| Study group | Role | What they receive |
|---|---|---|
| best medical care | Placebo comparator | All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively. Receives: Other: Standarad medical care |
| endovascular thrombectomy | Experimental | All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device. Receives: Device: endovascular thrombectomy (EVT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
modified Rankin Scale score (mRS)
global neurological functional outcome measured on the modified Rankin Scale
Measured: 90 days after randomization
Secondary outcomes (3)
National Institutes of Health Stroke Scale (NIHSS)
Stroke scale
Measured: 24 Hour
Mortality
All cause mortality
Measured: 90 days
European Quality of LIfe Scale (EQ-5D-5L)
Self reported health status
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2021
- Study start15 Apr 2022
- Primary completion31 Dec 2025 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- ESCAPE-MeVO is a multicenter, prospective, randomized, open- label study with blinded endpoint evaluation (PROBE design). Subjects will be allocated (1:1) to best guideline-based best medical care plus endovascular therapy (EVT) vs. best guideline- based best medical care alone.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 530 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr. Michael D Hill
- Sponsor type
- University, hospital or other
- Collaborators
- University of Calgary
- Responsible party
- Sponsor-investigator, Dr. Michael D Hill, University of Calgary
- Investigators
- Mayank Goyal, MD, Principal investigator, University of Calgary and Foothills Medical Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05151172
- Sponsor's protocol ID
- Version E, November 15, 2023
- Acronym
- ESCAPE-MeVO
- Status last verified
- Aug 2024
- First submitted
- 25 Nov 2021
- Last updated
- 15 Aug 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: We plan to share IPD in due course after the study is completed and published.
Publications
Pensato U, Jindal G, Diprose W, Ganesh A, Charatpangoon P, MacDonald E, Stebner A, Bosshart S, Dowlatshahi D, Volders D, Kennedy J, Mohlenbruch M, Buck BH, Nimjee S, Booth T, Jumaa M, Shankar JJ, Dorn F, Demchuk AM, Goyal M, Hill MD, Ospel JM; ESCAPE-MEVO Investigators. Thrombectomy for Acute Stroke Due to Medium Vessel Occlusion Across Perfusion Mismatch Profiles: A Post Hoc Analysis of the ESCAPE-MeVO Trial. JAMA Netw Open. 2026 Oct 1;9(10):e2638823. doi: 10.1001/jamanetworkopen.2026.38823.
PubMed 42867860Goyal M, Ospel JM, Ganesh A, Dowlatshahi D, Volders D, Mohlenbruch MA, Jumaa MA, Nimjee SM, Booth TC, Buck BH, Kennedy J, Shankar JJ, Dorn F, Zhang L, Hametner C, Nardai S, Zafar A, Diprose W, Vatanpour S, Stebner A, Bosshart S, Singh N, Sebastian I, Uchida K, Ryckborst KJ, Fahed R, Hu SX, Vollherbst DF, Zaidi SF, Lee VH, Lynch J, Rempel JL, Teal R, Trivedi A, Bode FJ, Ogungbemi A, Pham M, Orosz P, Abdalkader M, Taschner C, Tarpley J, Poli S, Singh RJ, De Leacy R, Lopez G, Sahlas D, Chen M, Burns P, Schaafsma JD, Marigold R, Reich A, Amole A, Field TS, Swartz RH, Settecase F, Lenzser G, Ortega-Gutierrez S, Asdaghi N, Lobotesis K, Siddiqui AH, Berrouschot J, Mokin M, Ebersole K, Schneider H, Yoo AJ, Mandzia J, Klostranec J, Jadun C, Patankar T, Sauvageau E, Lenthall R, Peeling L, Huynh T, Budzik R, Lee SK, Makalanda L, Levitt MR, Perry RJ, Hlaing T, Jahromi BS, Singh P, Demchuk AM, Hill MD; ESCAPE-MeVO Investigators. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025 Apr 10;392(14):1385-1395. doi: 10.1056/NEJMoa2411668. Epub 2025 Feb 5.
PubMed 39908448Ospel JM, Dowlatshahi D, Demchuk A, Volders D, Mohlenbruch M, Nimjee S, Kennedy J, Buck B, Shankar JJ, Booth TC, Jumaa MA, Fahed R, Ganesh A, Zhang Q, Doram C, Ryckborst KJ, Hill MD, Goyal M; ESCAPE-MeVO investigators. Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial. Int J Stroke. 2024 Oct;19(9):1064-1070. doi: 10.1177/17474930241262642. Epub 2024 Jun 20.
PubMed 38845180
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicentre, Prospective, Randomized, Parallel Group, Open-label Design to Determine the Efficacy and Safety of Endovascular Thrombectomy for Ischemic Stroke Patients With Symptomatic Acute Medium Vessel Intracranial Occlusions
- ClinicalTrials.gov ID
- NCT05151172
- Acronym / sponsor ID
- ESCAPE-MeVO / Version E, November 15, 2023
- Conditions
- Acute Ischemic Stroke
- Keywords
- endovascular thrombectomy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 530 participants (estimated)
- Lead sponsor
- Dr. Michael D HillUniversity, hospital or other
- Collaborators
- University of Calgary
- Study start
- 15 Apr 2022 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 9 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stroke occurs when a blood clot causes a blockage in a blood vessel (artery) within the brain. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. Stroke must be treated very fast. Any delay of even 10 minutes can result in the difference between an independent and a disabled outcome, and in some cases between life and death. Endovascular therapy (EVT) or Thrombectomy is a procedure to remove the blood clot (thrombus) from a blood vessel to reopen it (recanalization). Patients are likely to benefit from a thrombectomy procedure when it is performed in a larger blood vessel. Currently it is not known if thrombectomy procedure will benefit the patients presenting with the stroke that has been caused by a blood clot in a medium sized blood vessel (medium vessel occlusion, MeVO). This trial will enrol patients diagnosed with acute stroke due to a clot in the medium sized vessel. The patients will be randomized within 12 hours of their symptom onset to either standard of care or standard of care plus thrombectomy procedure. The participation will last for 12 months Escape MeVO coordinating centre is located at the University of Calgary. There will be up to 75 sites. We will be recruiting a total of 530 patients.
Detailed description
ESCAPE-MeVO is a multicenter, prospective, randomized, open- label study with blinded endpoint evaluation (PROBE design). Participants will be randomized to routine best medical stroke care governed by current guidelines (control group) or to EVT plus best medical care. EVT will be performed with one of the Solitaire group of intracranial stent-retriever devices (Solitaire X, Medtronic) as the first line approach according to the manufacturers' specifications for use.
Patients with clinical symptoms of acute stroke, last seen normal within the last 12 hours, and with either NIHSS ≥ 5 or NIHSS 3-5 due to disabling symptoms in the judgement of the stroke team shall undergo imaging to identify the MeVO and assess the status of the affected brain parenchyma. As is being currently practiced across different stroke centers, imaging may follow different imaging paradigms:
- Option 1: NCCT + mCTA (first phase covers intracranial and extracranial vessels)
- Option 2: NCCT + mCTA/spCTA + either mCTA tissue level perfusion maps or CTP perfusion maps
- Option 3: DWI-MRI + MRA (of both the intracranial and extracranial vessels). Approach to the EVT procedure and technique will be at the discretion of the interventionist and team, with the exception that the first thrombectomy attempt is performed with one of the Solitaire group of intracranial stent-retriever devices (Solitaire X, Medtronic). Available, approved off-the-shelf, secondary devices may be used if reperfusion success is not achieved after use of the first device, at the discretion of the neuro-interventionalist
This study consists of one 90-day study period for each participant. Participants will be hospitalized for care after their acute stroke according to the current standard of care. Participants are required to return to clinic on Day 90 for end-of-study assessment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- ESCAPE-MeVO is a multicenter, prospective, randomized, open- label study with blinded endpoint evaluation (PROBE design). Subjects will be allocated (1:1) to best guideline-based best medical care plus endovascular therapy (EVT) vs. best guideline- based best medical care alone.
| Arm | Type | Receives |
|---|---|---|
| best medical care | Placebo comparator | Other: Standarad medical careAll patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively. |
| endovascular thrombectomy | Experimental | Device: endovascular thrombectomy (EVT)All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Acute ischemic stroke clinically eligible for immediate EVT
- Age ≥18 years at the date of randomization
- Time from onset (or last-seen-well) to randomization <12 hours
- Disabling stroke defined as follows:
- Confirmed symptomatic and endovascularly treatable MeVO based on neurovascular non-invasive imaging (mCTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P2 or P3 segment1.
Key exclusion criteria (9 listed)
- ASPECTS ≤ 5
- The following depend on the imaging modality of the participating site:
- 9a. NCCT + mCTA
- Well demarcated hypodensity in the majority of the brain parenchyma supplied by the occluded vessel or absence of collaterals in the affected territory on the delayed phases of the mCTA OR 9b. NCCT + (m)CTA + CTP**
- Lack of core: penumbra mismatch (if the CTP is uninterpretable, e.g., due to motion artifacts, apply exclusion criteria from 9a. If single-phase CTA is performed, score collaterals accordingly. If NCCT + mCTA + CTP are all performed, the core: penumbra mismatch criteria are sufficient for exclusion) OR 9c. MRI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endovascular thrombectomy (EVT)Also: solitaire Xminimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus | Device | endovascular thrombectomy |
| Standarad medical careStanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs | Other | best medical care |
Primary outcome
modified Rankin Scale score (mRS)
Time frame: 90 days after randomization
global neurological functional outcome measured on the modified Rankin Scale
3 secondary outcomes
National Institutes of Health Stroke Scale (NIHSS)
Time frame: 24 Hour
Mortality
Time frame: 90 days
European Quality of LIfe Scale (EQ-5D-5L)
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2024.
- Derived from this study: PubMed 42867860Pensato U, Jindal G, Diprose W, Ganesh A, Charatpangoon P, MacDonald E, Stebner A, Bosshart S, Dowlatshahi D, Volders D, Kennedy J, Mohlenbruch M, Buck BH, Nimjee S, Booth T, Jumaa M, Shankar JJ, Dorn F, Demchuk AM, Goyal M, Hill MD, Ospel JM; ESCAPE-MEVO Investigators. Thrombectomy for Acute Stroke Due to Medium Vessel Occlusion Across Perfusion Mismatch Profiles: A Post Hoc Analysis of the ESCAPE-MeVO Trial. JAMA Netw Open. 2026 Oct 1;9(10):e2638823. doi: 10.1001/jamanetworkopen.2026.38823.
- Derived from this study: PubMed 39908448Goyal M, Ospel JM, Ganesh A, Dowlatshahi D, Volders D, Mohlenbruch MA, Jumaa MA, Nimjee SM, Booth TC, Buck BH, Kennedy J, Shankar JJ, Dorn F, Zhang L, Hametner C, Nardai S, Zafar A, Diprose W, Vatanpour S, Stebner A, Bosshart S, Singh N, Sebastian I, Uchida K, Ryckborst KJ, Fahed R, Hu SX, Vollherbst DF, Zaidi SF, Lee VH, Lynch J, Rempel JL, Teal R, Trivedi A, Bode FJ, Ogungbemi A, Pham M, Orosz P, Abdalkader M, Taschner C, Tarpley J, Poli S, Singh RJ, De Leacy R, Lopez G, Sahlas D, Chen M, Burns P, Schaafsma JD, Marigold R, Reich A, Amole A, Field TS, Swartz RH, Settecase F, Lenzser G, Ortega-Gutierrez S, Asdaghi N, Lobotesis K, Siddiqui AH, Berrouschot J, Mokin M, Ebersole K, Schneider H, Yoo AJ, Mandzia J, Klostranec J, Jadun C, Patankar T, Sauvageau E, Lenthall R, Peeling L, Huynh T, Budzik R, Lee SK, Makalanda L, Levitt MR, Perry RJ, Hlaing T, Jahromi BS, Singh P, Demchuk AM, Hill MD; ESCAPE-MeVO Investigators. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025 Apr 10;392(14):1385-1395. doi: 10.1056/NEJMoa2411668. Epub 2025 Feb 5.
- Derived from this study: PubMed 38845180Ospel JM, Dowlatshahi D, Demchuk A, Volders D, Mohlenbruch M, Nimjee S, Kennedy J, Buck B, Shankar JJ, Booth TC, Jumaa MA, Fahed R, Ganesh A, Zhang Q, Doram C, Ryckborst KJ, Hill MD, Goyal M; ESCAPE-MeVO investigators. Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial. Int J Stroke. 2024 Oct;19(9):1064-1070. doi: 10.1177/17474930241262642. Epub 2024 Jun 20.
- Individual participant dataSharing planned: Yes. We plan to share IPD in due course after the study is completed and published.
Related trials for Acute Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mayank Goyal, MD principal investigator
University of Calgary and Foothills Medical Centre
53 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing endovascular thrombectomy (EVT) and Standarad medical care in people with Acute Ischemic Stroke, run by Dr. Michael D Hill at 53 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 53 sites in United States, Canada, United Kingdom, Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
modified Rankin Scale score (mRS) (time frame: 90 days after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05151172, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2024.